Legal status by country
Is Senolytic CAR T cells legal?
Written by Aaron CuhaReviewed Sep 2026
How Senolytic CAR T cells is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Investigational, not approved | Investigational, not licensed | Investigational, not registered | Investigational, not approved |
| Note | Preclinical for senescence. Approved CAR T products exist for blood cancers only, and are administered in hospital after lymphodepleting chemotherapy. | No senescence indication. Not obtainable outside a trial, and no such trial exists. | No senescence indication. | No senescence indication. |
US FDA status: No senolytic CAR T product is approved, and none is in a registered human trial for ageing or senescence. CAR T therapy as a class is approved in the United States for certain blood cancers, which is a different target, a different patient and a different risk calculation.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.